Managing Partner, Montreal and Munich
Dr. Birner is responsible for TVM Capital Life Science’s overall investment strategy and fund operations in North America and Europe. He also serves as a member of the fund advisory board of TVM Capital Life Science’s China BioPharma Capital I fund.
Dr. Birner joined TVM Capital in 2000 as an investment manager. He currently serves as Chairman of the Board of Argos Therapeutics Inc. (Durham, North Carolina, NASDAQ), Spepharm Holdings BV (Amsterdam, the Netherlands), Noxxon AG (Berlin, Germany) and leon nanodrugs (Munich, Germany). He is a member of the Board of Directors of Proteon Therapeutics, Inc (Waltham, Massachusetts, NASDAQ) and represents the firm’s interests in Evotec AG (Hamburg, Germany, XETRA) as well as Probiodrug AG (Halle, Germany, EURONEXT). For many years he has been the Chairman/Vice Chairman of the Board of Direvo Biotech AG (Cologne, Germany) and Jerini AG (Berlin, Germany) which were acquired in 2008 by Bayer HealthCare AG and Shire Ltd., respectively.
Prior to his tenure at TVM Capital, he was Head of Business Development Europe and Director of Marketing for Germany at Zeneca. Dr. Birner joined Zeneca from McKinsey & Company’s European Health Care and Pharmaceutical practice. As a management consultant he gained extensive experience in R&D management, marketing and sales, and joint venture structuring and business development.
Before starting his professional career in business, he earned substantial academic merits, including a position as Assistant Professor for biochemistry at the Ludwig-Maximilian-University (LMU), following his summa cum laude doctoral degree in biochemistry at LMU; his doctoral thesis was honored with the Hoffmann-La Roche prize for outstanding basic research in metabolic diseases. Dr. Birner additionally holds an MBA from Harvard Business School.